ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Accuracy of C2HEST and HARSM2-AF Scores in Predicting Atrial Fibrillation After Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionThe new onset atrial fibrillation (NOAF) is a complication that should not be dismissed after an acute coronary syndrome since this association is characterized by a high ischemic risk.MethodsWe investigated the performance of C2HEST and the HARMS2-AF scores for predicting NOAF during hospitalization in patients admitted with ACS treated with percutaneous coronary intervention (PCI).ResultsAmong the 763 patients eligible for the inclusion criteria, 64 patients developed NOAF during the index hospitalization, with an incidence of 8.38%. For the C2HEST score, the mean score in the NOAF group was higher than in the other group [NOAF versus No NOAF: 2.45 (± 1.79) versus 1.27 (± 1.43), p < 0.001], and ROC analysis showed good accuracy of C2HEST score in predicting NOAF with cut-off ≥3 [AUC = 0.699; 95%CI [0.665; 0.731], p < 0.001]. For the HARMS2-AF score, the mean score in the NOAF group was higher than in the other group [NOAF versus No NOAF: 9.22 (± 3.5) versus 6.72 (± 2.94), p < 0.001] and ROC analysis showed good accuracy of C2HEST score in predicting NOAF with cut-off≥7 [AUC = 0.722; 95%CI [0.689; 0.754], p < 0.001], and the comparison of the two scores found no significant difference with de long test p value at 0.326. A multivariate logistic regression analysis showed that C2HEST score >3 (OR = 1.86, p = 0.043) and HARMS2-AF >7 (OR = 3.91, p < 0.001) were independently associated with NOAF.ConclusionThe C2HEST and HARMS2-AF are simple scores that can predict NOAF in patients with ACS treated with PCI with good accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.